Claims for GLP-1s Increased Four-Fold Between 2019 and 2024 In accordance with an increase in both the number of Medicare Part D enrollees using GLP-1s and spending on these products, the number of claims for GLP-1s increased four-fold between 2019 and 2024, from 4.8 million to 21.8 million, with claims doubling between 2022 and 2024 alone
Clinical context on this medication class (for informational purposes only): In clinical trials involving FDA-approved branded medications, both semaglutide and tirzepatide have produced meaningful average weight-loss results in specific study populations
PlexusDx sources exclusively from regulated 503A facilities that conduct rigorous quality testing
Chicken nugget type, dextrose anhydrous, potassium sorbate,, caramel color, purified water
Assuming a higher number is automatically better can overlook the safety reasoning behind gradual, provider-guided pacing
They may refer you to a reputable U.S.-based compounding pharmacy or suggest other prescription weight loss alternatives